2024
0568 Promoting Shared Decision Making with a Novel Self-Monitoring Program for Veterans with Obstructive Sleep Apnea
Mak S, Ghadimi S, Der-Mcleod E, Moore V, Naeem S, Chohan M, Zeidler M, Ash G, Fung C. 0568 Promoting Shared Decision Making with a Novel Self-Monitoring Program for Veterans with Obstructive Sleep Apnea. Sleep 2024, 47: a243-a243. DOI: 10.1093/sleep/zsae067.0568.Peer-Reviewed Original ResearchObstructive sleep apneaObstructive sleep apnea treatmentSleep apneaShared decision makingPAP therapyOSA treatmentAirway pressurePAP treatmentSleep centerTreatment optionsTreatment successDaytime sleepinessSleep cliniciansAlternative therapiesPatientsPulse oximetryTherapyTherapy effectsSpO2 dataApneaTreatmentQuality improvement projectPAPSpO2Patient preference elicitation
2023
Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics
Dodd P, Shaweno D, Ku C, Glaziou P, Pretorius C, Hayes R, MacPherson P, Cohen T, Ayles H. Transmission modeling to infer tuberculosis incidence prevalence and mortality in settings with generalized HIV epidemics. Nature Communications 2023, 14: 1639. PMID: 36964130, PMCID: PMC10037365, DOI: 10.1038/s41467-023-37314-1.Peer-Reviewed Original ResearchConceptsHigh HIV prevalence settingsEstimation of burdenHIV prevalence settingsGeneralized HIV epidemicsTB transmission modelAntiretroviral therapyTB infectionTB incidenceHIV prevalenceTB prevalencePrevalence settingsTB epidemicHIV epidemicHigh burdenBurden estimatesNotification dataAnnual riskSingle pathogenIntervention impactTherapy effectsTuberculosisPrevalenceEpidemicBurdenAfrican countriesPsilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
Sloshower J, Skosnik P, Safi-Aghdam H, Pathania S, Syed S, Pittman B, D’Souza D. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Journal Of Psychopharmacology 2023, 37: 698-706. PMID: 36938991, DOI: 10.1177/02698811231154852.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAntidepressant effectsDepressive disorderSevere major depressive disorderPsilocybin-assisted therapyEarly phase studiesQuality of lifeClinical improvementDosing sessionsMajor depressionPsilocybin administrationPlacebo effectPsychotherapeutic supportPlaceboTherapy effectsStudy periodPsychotherapy studiesFurther studiesSignificant differencesDepressionDosingTherapyHigh rateEffect sizeDegree of change
2021
Is the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging
Xu M, Demuyakor A, Hu S, Liu H, Zhao C, Chen T, Qin Y, Xu Y, Feng X, Zeng M, Weng Z, Gao Z, Hou J, Jia H, Zhang S, Yu B. Is the effect of atorvastatin 60 mg on stabilization of lipid‐rich plaque equivalent to that of rosuvastatin 10 mg? A serial optical coherence tomography combined with intravascular ultrasound imaging. Catheterization And Cardiovascular Interventions 2021, 97: 1097-1107. PMID: 33864710, DOI: 10.1002/ccd.29654.Peer-Reviewed Original ResearchConceptsOptical coherence tomographyLipid-rich plaquesLipid lowering therapyEffect of atorvastatinFibrous cap thicknessStatin therapyLowering therapyCoherence tomographyIntensive lipid lowering therapySerial optical coherence tomographyCholesterol levelsLow-density lipoprotein cholesterol levelsIntravascular ultrasound imagingLipoprotein cholesterol levelsCholesterol level reductionLipid arcClinical benefitFollow-upPlaque volumeUltrasound imagingTherapyTherapy effectsPlaque burdenPercentage changeStatins
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply